These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 39123403)
1. IFNγ-Induced Bcl3, PD-L1 and IL-8 Signaling in Ovarian Cancer: Mechanisms and Clinical Significance. Reddy SU; Sadia FZ; Vancura A; Vancurova I Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123403 [TBL] [Abstract][Full Text] [Related]
2. The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells. Zou Y; Uddin MM; Padmanabhan S; Zhu Y; Bu P; Vancura A; Vancurova I J Biol Chem; 2018 Oct; 293(40):15483-15496. PubMed ID: 30135206 [TBL] [Abstract][Full Text] [Related]
3. IFNγ induces Bcl3 expression by JAK1/STAT1/p65 signaling, resulting in increased IL-8 expression in ovarian cancer cells. Gaire B; Padmanabhan S; Zou Y; Uddin MM; Reddy SU; Vancurova I FEBS Open Bio; 2023 Aug; 13(8):1495-1506. PubMed ID: 37151134 [TBL] [Abstract][Full Text] [Related]
4. Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-γ-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA. Padmanabhan S; Zou Y; Vancurova I Methods Mol Biol; 2020; 2108():211-220. PubMed ID: 31939183 [TBL] [Abstract][Full Text] [Related]
5. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543 [TBL] [Abstract][Full Text] [Related]
6. IFNγ induces JAK1/STAT1/p65 NFκB-dependent interleukin-8 expression in ovarian cancer cells, resulting in their increased migration. Padmanabhan S; Gaire B; Zou Y; Uddin MM; DeLeon D; Vancurova I Int J Biochem Cell Biol; 2021 Dec; 141():106093. PubMed ID: 34626802 [TBL] [Abstract][Full Text] [Related]
7. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma. Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral Delivery of an Adenoviral Vector Carrying the Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489 [TBL] [Abstract][Full Text] [Related]
10. Analysis of IFNγ-Induced Migration of Ovarian Cancer Cells. Gaire B; Uddin MM; Zou Y; Vancurova I Methods Mol Biol; 2020; 2108():101-106. PubMed ID: 31939173 [TBL] [Abstract][Full Text] [Related]
11. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259 [TBL] [Abstract][Full Text] [Related]
12. Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment. Cheng CC; Chang J; Ho AS; Sie ZL; Peng CL; Wang CL; Dev K; Chang CC Cancer Immunol Immunother; 2024 Jul; 73(9):175. PubMed ID: 38953994 [TBL] [Abstract][Full Text] [Related]
13. IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study. Yuan W; Deng D; Li H; Hu X; Shang X; Hou X; Jiang H; He H Onco Targets Ther; 2021; 14():3051-3062. PubMed ID: 33994797 [TBL] [Abstract][Full Text] [Related]
14. Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I Clin Cancer Res; 2016 May; 22(10):2329-34. PubMed ID: 27016309 [TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. Shang A; Wang W; Gu C; Chen C; Zeng B; Yang Y; Ji P; Sun J; Wu J; Lu W; Sun Z; Li D J Exp Clin Cancer Res; 2019 Sep; 38(1):411. PubMed ID: 31533774 [TBL] [Abstract][Full Text] [Related]
16. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Bellucci R; Martin A; Bommarito D; Wang K; Hansen SH; Freeman GJ; Ritz J Oncoimmunology; 2015 Jun; 4(6):e1008824. PubMed ID: 26155422 [TBL] [Abstract][Full Text] [Related]
17. Tofacitinib overcomes an IFNγ-induced decrease in NK cell-mediated cytotoxicity via the regulation of immune-related molecules in LC-2/ad. Okita R; Shimizu K; Nojima Y; Saisho S; Nakata M Thorac Cancer; 2021 Mar; 12(6):775-782. PubMed ID: 33491334 [TBL] [Abstract][Full Text] [Related]
18. Flow Cytometry Analysis of Surface PD-L1 Expression Induced by IFNγ and Romidepsin in Ovarian Cancer Cells. Padmanabhan S; Zou Y; Vancurova I Methods Mol Biol; 2020; 2108():221-228. PubMed ID: 31939184 [TBL] [Abstract][Full Text] [Related]
19. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma. van Duijn A; Willemsen KJ; van Uden NOP; Hoyng L; Erades S; Koster J; Luiten RM; Bakker WJ Cancer Immunol Immunother; 2022 Mar; 71(3):529-540. PubMed ID: 34268602 [TBL] [Abstract][Full Text] [Related]
20. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]